This site is intended for health professionals only
Hospira Aseptic Services Limited, the UK based compounding business of Hospira, today announced a new 10-year contract with The Royal Marsden NHS Foundation Trust to be its provider of aseptic compounding services.
This agreement represents the largest single outsourced compounding contract awarded by tender by an NHS organisation.
Since acquiring Intratech/Mayne Pharma in 2007, Hospira has been able to enhance the value of its generic drug and oncology-specific offerings by providing aseptic compounding services for a variety of clients across the United Kingdom.
This knowledge and experience positions Hospira to offer a high quality, cost-effective range of aseptically prepared oncology medicines from a new, modern unit to be built in south London near The Royal Marsden’s Sutton site.
Compounding is a service that requires the mixing of drugs in order to produce ready-to-administer medications. These services, as required by oncology centres such as The Royal Marsden, are complex and time sensitive, due to customised individual patient treatment regimes.
“An efficient and effective compounding service can reduce cost, improve quality and, most importantly, improve the patient’s treatment experience,” said Michael Kotsanis, president, Europe, Middle East & Africa, Hospira. “Hospira is delighted to have been selected to work in partnership with The Royal Marsden, a world-renowned cancer centre.”
David Probert, Chief Operating Officer at The Royal Marsden, said: “This new partnership shows great co-operation between the pharmaceutical industry and the NHS. It is one that will ultimately benefit our patients and shows The Royal Marsden’s continued commitment to providing the best possible service and treatments.”
The Royal Marsden’s Chief Pharmacist Ian Costello said: “This exciting collaboration brings together the strengths of the two organizations to deliver a high quality chemotherapy service to patients.”